作者
Mikhail Kosiborod, Carolyn SP Lam, Shun Kohsaka, Dae Jung Kim, Avraham Karasik, Jonathan Shaw, Navdeep Tangri, Su-Yen Goh, Marcus Thuresson, Hungta Chen, Filip Surmont, Niklas Hammar, Peter Fenici, CVD-REAL Investigators and Study Group
发表日期
2018/6/12
期刊
Journal of the American College of Cardiology
卷号
71
期号
23
页码范围
2628-2639
出版商
American College of Cardiology Foundation
简介
Background
Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at high CV risk. Prior real-world data suggested similar SGLT-2i effects in T2D patients with a broader risk profile, but these studies focused on heart failure and death and were limited to the United States and Europe.
Objectives
The purpose of this study was to examine a broad range of CV outcomes in patients initiated on SGLT-2i versus other glucose-lowering drugs (oGLDs) across 6 countries in the Asia Pacific, the Middle East, and North American regions.
Methods
New users of SGLT-2i and oGLDs were identified via claims, medical records, and national registries in South Korea, Japan, Singapore, Israel, Australia, and Canada. Propensity scores for SGLT-2i initiation were developed in each country, with 1:1 matching …
学术搜索中的文章
M Kosiborod, CSP Lam, S Kohsaka, DJ Kim, A Karasik… - Journal of the American College of Cardiology, 2018